Researchers at Nagoya University have discovered that a protein called complement C3, which evolved long before blood circulation, could enhance cancer immunotherapy. This ancient immune molecule, when produced within tumors, blocks immune-suppressing cells, allowing the immune system to better target and attack cancer cells. In experiments with mice, the presence of local C3 significantly improved survival rates, suggesting a potential breakthrough in treating stubborn, treatment-resistant tumors.

This finding is particularly relevant for individuals facing cancer, as it highlights the importance of C3 levels within the tumor environment. People with tumors that produce higher levels of local C3 may experience better treatment outcomes and longer survival rates. In a study of lung cancer patients, those with elevated local C3 levels responded positively to immunotherapy, while those with lower levels did not respond at all. This suggests that measuring local C3 could help doctors identify which patients are more likely to benefit from immunotherapy.

The research is still in the early stages, primarily involving mouse models and analysis of human tumor samples. While the results are promising, they are not yet proven in large human trials. The next steps for researchers include exploring ways to increase C3 levels in tumors and determining the best timing for treatment. Understanding the role of C3 could also shed light on other biological processes, such as wound healing and inflammation regulation.

Source: Science Daily